Patent intelligence · Companies
Company patent strength
Non-educational filers ranked by their patent portfolio. Grant rate and lapsed share expose where high filing volume is not matched by granted patents. Domestic filers lead — toggle to foreign applicants to see who is entering the Indian market.
Free to browse the ranking. Sign into open a filer's full profile — inventors, filing trend and quality index. See how we rank.
Why this page exists — and how to read it
Filing volume and IP quality are different things. This leaderboard ranks non-educational filers by portfolio, but the grant-rate and lapsed sorts are where the judgement lives: they separate companies whose filings survive examination from those accumulating paper.
- Investors
- High grant rate on steady filing usually means a real R&D engine; big volume with a high lapsed share is a red flag worth asking about.
- Founders & operators
- These are the incumbents and potential acquirers in your space — open a filer to see the walls you'd build against.
- Corporate & R&D
- Benchmark competitors' portfolios and grant rates; toggle to foreign to watch who is entering the Indian market.
💬 The grant-rate sort applies a 20-filing floor so tiny portfolios can't top the list.
3,207 foreign filers with 5+ patents · page 37
| # | Filer | Patents↓ | Granted↓ | Lapsed↓ | Pending↓ | Active |
|---|---|---|---|---|---|---|
| 1801 | JIANGSU LEADMICRO NANO TECHNOLOGY | 8 | 00% | 0 | 8 | 2024–2026 |
| 1802 | JOY GLOBAL SURFACE MINING | 8 | 112.5% | 0 | 7 | 2020–2026 |
| 1803 | JUPENG BIO HK | 8 | 00% | 0 | 8 | 2022–2025 |
| 1804 | KADANT BLACK CLAWSON | 8 | 225% | 0 | 6 | 2021–2026 |
| 1805 | KANGBAIDA SICHUAN BIOTECHNOLOGY | 8 | 225% | 0 | 6 | 2022–2026 |
| 1806 | KEDA INDUSTRIAL GROUP | 8 | 00% | 0 | 8 | 2023–2025 |
| 1807 | KEWPIE | 8 | 00% | 0 | 8 | 2023–2026 |
| 1808 | KM BIOLOGICS | 8 | 00% | 0 | 8 | 2022–2026 |
| 1809 | KMW | 8 | 675% | 0 | 2 | 2022–2024 |
| 1810 | KOCH GLITSCH LP | 8 | 00% | 0 | 8 | 2024–2026 |
| 1811 | KRONOS INTERNATIONAL | 8 | 00% | 2 | 6 | 2022–2026 |
| 1812 | KY7 | 8 | 225% | 0 | 6 | 2022–2025 |
| 1813 | KYOWA PHARMA CHEMICAL | 8 | 112.5% | 0 | 7 | 2022–2026 |
| 1814 | LABORATORY OF AMERICA HOLDINGS | 8 | 00% | 1 | 7 | 2022–2025 |
| 1815 | LANDIS GYR INNOVATIONS | 8 | 112.5% | 0 | 7 | 2022–2023 |
| 1816 | LARIMAR THERAPEUTICS | 8 | 00% | 0 | 8 | 2022–2024 |
| 1817 | LECTRA | 8 | 00% | 0 | 8 | 2022–2026 |
| 1818 | LINDAL FRANCE | 8 | 225% | 2 | 4 | 2022–2026 |
| 1819 | LIQMEDS WORLDWIDE | 8 | 00% | 0 | 8 | 2023–2024 |
| 1820 | LYNRED | 8 | 00% | 1 | 7 | 2023–2025 |
| 1821 | MAGNUS METAL | 8 | 00% | 0 | 8 | 2023–2026 |
| 1822 | MANN HUMMEL LIFE SCIENCES ENVIRONMENT HOLDING SINGAPORE | 8 | 112.5% | 0 | 7 | 2023–2025 |
| 1823 | MANNKIND | 8 | 225% | 0 | 6 | 2018–2025 |
| 1824 | MARPOSS SOCIETA PER AZIONI | 8 | 112.5% | 0 | 7 | 2022–2025 |
| 1825 | MASCHIO GASPARDO | 8 | 00% | 0 | 8 | 2022–2026 |
| 1826 | MAXION WHEELS HOLDING | 8 | 112.5% | 0 | 7 | 2022–2024 |
| 1827 | MENARINI SILICON BIOSYSTEMS | 8 | 112.5% | 0 | 7 | 2021–2026 |
| 1828 | MERSANA THERAPEUTICS | 8 | 00% | 0 | 8 | 2022–2024 |
| 1829 | METHODICAL MIND | 8 | 225% | 0 | 6 | 2021–2026 |
| 1830 | MFTB HOLDCO | 8 | 450% | 1 | 3 | 2021–2023 |
| 1831 | MICROPORT ORTHOPEDICS HOLDINGS | 8 | 00% | 0 | 8 | 2023–2026 |
| 1832 | MODEX THERAPEUTICS | 8 | 00% | 0 | 8 | 2024–2026 |
| 1833 | MOENGAGE | 8 | 00% | 0 | 8 | 2023–2025 |
| 1834 | MOTHERSON INNOVATIONS | 8 | 00% | 0 | 8 | 2023–2026 |
| 1835 | NABRAWIND TECHNOLOGIES S L | 8 | 00% | 0 | 8 | 2024–2025 |
| 1836 | NEXTERN INNOVATION | 8 | 00% | 5 | 3 | 2022–2022 |
| 1837 | NIKKI | 8 | 00% | 0 | 8 | 2022–2025 |
| 1838 | NIPPON CHEMIPHAR | 8 | 337.5% | 1 | 4 | 2022–2025 |
| 1839 | NIPPON TANSHI | 8 | 00% | 0 | 8 | 2023–2026 |
| 1840 | NISSHINBO HOLDINGS | 8 | 337.5% | 1 | 4 | 2022–2025 |
| 1841 | NITTA | 8 | 00% | 0 | 8 | 2022–2025 |
| 1842 | NORTHROP GRUMMAN SYSTEMS | 8 | 562.5% | 0 | 3 | 2022–2024 |
| 1843 | NOZOMI NETWORKS SAGL | 8 | 00% | 0 | 8 | 2022–2023 |
| 1844 | ORIGAMI SOLAR | 8 | 00% | 0 | 8 | 2023–2025 |
| 1845 | OSG | 8 | 00% | 0 | 8 | 2023–2026 |
| 1846 | OSLER DIAGNOSTICS | 8 | 00% | 0 | 8 | 2023–2026 |
| 1847 | OUTSENSE DIAGNOSTICS | 8 | 00% | 1 | 7 | 2022–2025 |
| 1848 | OVID THERAPEUTICS | 8 | 00% | 0 | 8 | 2024–2025 |
| 1849 | OYSTER POINT PHARMA | 8 | 00% | 0 | 8 | 2023–2025 |
| 1850 | PACKSIZE | 8 | 00% | 5 | 3 | 2022–2023 |
Educational institutes are excluded — see the institute leaderboard. Attribution is by patent assignee record; a jointly-owned patent is credited to each co-owner, so a co-filed patent counts for every company on it. "Lapsed" = abandoned, withdrawn, deemed-withdrawn or refused; "Pending" = awaiting examination or in prosecution. Want to filter by technology or value category? Browse the filer explorer →
Rankings use patent-registry status (grant rate, examination, claim depth) as a quality proxy — directional, not advice; see methodology. Read the ranking methodology →